Published in J Immunother Cancer on August 16, 2016
The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets. Immunol Rev (2017) 0.80
Prostaglandin E2-mediated adenosinergic effects on CD14(+) cells: Self-amplifying immunosuppression in cancer. Oncoimmunology (2016) 0.75
Changes in CD73, CD39 and CD26 expression on T-lymphocytes of ANCA-associated vasculitis patients suggest impairment in adenosine generation and turn-over. Sci Rep (2017) 0.75
Targeting immunosuppressive adenosine in cancer. Nat Rev Cancer (2017) 0.75
The interplay between metabolic remodeling and immune regulation in glioblastoma. Neuro Oncol (2017) 0.75
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 22.96
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med (2003) 16.62
Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer (2004) 14.55
Macrophage diversity enhances tumor progression and metastasis. Cell (2010) 13.41
Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med (2007) 10.00
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med (2009) 6.73
Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest (2007) 6.31
Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature (2009) 4.98
Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov (2008) 4.76
Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol (2010) 4.62
P2X receptors as cell-surface ATP sensors in health and disease. Nature (2006) 4.55
A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci U S A (2006) 4.25
Adenosine: an endogenous regulator of innate immunity. Trends Immunol (2004) 4.07
Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer (2012) 3.76
History of myeloid-derived suppressor cells. Nat Rev Cancer (2013) 3.14
Extracellular ATP triggers and maintains asthmatic airway inflammation by activating dendritic cells. Nat Med (2007) 2.85
Extracellular ATP triggers IL-1 beta release by activating the purinergic P2Z receptor of human macrophages. J Immunol (1997) 2.81
Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr Relat Cancer (2012) 2.74
Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc Natl Acad Sci U S A (2010) 2.67
Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. J Immunol (2006) 2.67
Ecto-enzyme and signaling functions of lymphocyte CD73. Immunol Rev (1998) 2.46
Prognostic and predictive impact of intra- and peritumoral immune infiltrates. Cancer Res (2011) 2.16
CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. Cancer Res (2010) 2.13
The adenosine/neutrophil paradox resolved: human neutrophils possess both A1 and A2 receptors that promote chemotaxis and inhibit O2 generation, respectively. J Clin Invest (1990) 2.12
Adenosinergic regulation of the expansion and immunosuppressive activity of CD11b+Gr1+ cells. J Immunol (2011) 2.05
The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. Cancer Res (1997) 1.95
Macrophage responses to hypoxia: implications for tumor progression and anti-cancer therapies. Am J Pathol (2005) 1.85
Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity. Cancer Res (2010) 1.82
High expression of CD73 as a poor prognostic biomarker in human colorectal cancer. J Surg Oncol (2012) 1.81
Notch signaling determines the M1 versus M2 polarization of macrophages in antitumor immune responses. Cancer Res (2010) 1.70
Disordered cellular migration and angiogenesis in cd39-null mice. Circulation (2001) 1.70
Detection of M2 macrophages and colony-stimulating factor 1 expression in serous and mucinous ovarian epithelial tumors. Pathol Int (2009) 1.68
Macrophage arginase promotes tumor cell growth and suppresses nitric oxide-mediated tumor cytotoxicity. Cancer Res (2001) 1.62
Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review). Int J Oncol (2008) 1.58
CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. Proc Natl Acad Sci U S A (2013) 1.54
CD73: a potent suppressor of antitumor immune responses. Trends Immunol (2012) 1.52
Anti-tumour strategies aiming to target tumour-associated macrophages. Immunology (2013) 1.40
CD73-deficient mice are resistant to carcinogenesis. Cancer Res (2012) 1.38
Regulation of tumor metastasis by myeloid-derived suppressor cells. Annu Rev Med (2014) 1.29
Mixed-polarization phenotype of ascites-associated macrophages in human ovarian carcinoma: correlation of CD163 expression, cytokine levels and early relapse. Int J Cancer (2013) 1.27
The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. Trends Immunol (2016) 1.20
A novel cyclic adenosine monophosphate responsive luciferase reporter incorporating a nonpalindromic cyclic adenosine monophosphate response element provides optimal performance for use in G protein coupled receptor drug discovery efforts. J Biomol Screen (2007) 1.20
GRO family chemokines are specialized for monocyte arrest from flow. Am J Physiol Heart Circ Physiol (2005) 1.20
Regulation of enteric functions by adenosine: pathophysiological and pharmacological implications. Pharmacol Ther (2008) 1.19
Adenosine promotes neutrophil chemotaxis. J Exp Med (1988) 1.18
Deletion of cd39/entpd1 results in hepatic insulin resistance. Diabetes (2008) 1.18
Adenosine A2A receptor activation inhibits T helper 1 and T helper 2 cell development and effector function. FASEB J (2008) 1.16
Expression of M2-polarized macrophages is associated with poor prognosis for advanced epithelial ovarian cancer. Technol Cancer Res Treat (2012) 1.11
Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity. Cancer Immunol Immunother (2011) 1.09
Biological functions of ecto-enzymes in regulating extracellular adenosine levels in neoplastic and inflammatory disease states. J Mol Med (Berl) (2013) 1.06
CD73 expression as a potential marker of good prognosis in breast carcinoma. Appl Immunohistochem Mol Morphol (2012) 1.06
"Host tissue damage" signal ATP promotes non-directional migration and negatively regulates toll-like receptor signaling in human monocytes. J Biol Chem (2005) 1.06
Inhibition of CD73 improves B cell-mediated anti-tumor immunity in a mouse model of melanoma. J Immunol (2012) 1.03
Adenosine signaling during acute and chronic disease states. J Mol Med (Berl) (2013) 1.02
Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment. Cancer Res (2014) 1.01
Macrophage scavenger receptor a promotes tumor progression in murine models of ovarian and pancreatic cancer. J Immunol (2013) 1.00
Adenosine A2A receptor activation protects CD4+ T lymphocytes against activation-induced cell death. FASEB J (2010) 1.00
Overexpression of CD73 in epithelial ovarian carcinoma is associated with better prognosis, lower stage, better differentiation and lower regulatory T cell infiltration. J Gynecol Oncol (2012) 0.97
Mononuclear phagocyte heterogeneity in cancer: different subsets and activation states reaching out at the tumor site. Immunobiology (2011) 0.96
The comprehensive assessment of local immune status of ovarian cancer by the clustering of multiple immune factors. Clin Immunol (2011) 0.93
Adenosine slows migration of dendritic cells but does not affect other aspects of dendritic cell maturation. J Invest Dermatol (2003) 0.91
A3 adenosine receptor agonist reduces brain ischemic injury and inhibits inflammatory cell migration in rats. Am J Pathol (2011) 0.91
Differential macrophage activation alters the expression profile of NTPDase and ecto-5'-nucleotidase. PLoS One (2012) 0.90
Mesenchymal stem cells tune the development of monocyte-derived dendritic cells toward a myeloid-derived suppressive phenotype through growth-regulated oncogene chemokines. J Immunol (2013) 0.90
CD45 Phosphatase Inhibits STAT3 Transcription Factor Activity in Myeloid Cells and Promotes Tumor-Associated Macrophage Differentiation. Immunity (2016) 0.88
Adenosine in fibrosis. Mod Rheumatol (2009) 0.86
Peritoneal immune system in patients with advance epithelial ovarian cancer. Int Rev Immunol (2011) 0.83
Novel effects of adenosine receptors on pericellular hyaluronan matrix: implications for human smooth muscle cell phenotype and interactions with monocytes during atherosclerosis. Basic Res Cardiol (2013) 0.81
A cell-based luciferase-dependent assay for the quantitative determination of free extracellular adenosine with paracrine signaling activity. J Immunol Methods (2010) 0.81
Effect of hypoxia and re-oxygenation on cell invasion and adhesion in human ovarian carcinoma cells. Oncol Rep (2008) 0.81
Purinergic Signaling During Immune Cell Trafficking. Trends Immunol (2016) 0.80
Regulatory T Cells from Colon Cancer Patients Inhibit Effector T-cell Migration through an Adenosine-Dependent Mechanism. Cancer Immunol Res (2016) 0.78